Objective: Evidence from cell and mouse models and human tissues suggests that cyclin dependent kinase 1 (CDK1) is involved in lung cancer (LC) tumorigenesis. However, the different types of expression patterns and prognostic results of CDK1 need further analysis.Methods: In the current study, we assessed CDK1 expression and LC patient outcomes using data from the Oncomine, GEPIA, and Kaplan-Meier Plotter databases. Additionally, mutations in the CDK1 gene were analyzed by using the cBioPortal database. The expression of CDK1 was verified by real-time quantitative PCR using the Human Protein Atlas database and human tissues. Results: Expression of CDK1 was higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in normal lung samples. Moreover, CDK1 expression was linked to disease progression. Survival analysis indicated that upregulation of CDK1 was related to poor overall survival, low first progression, and post-progression survival in patients with LC. Conclusions: Our results indicate that CDK1 is a potential clinical target and prognostic biomarker for patients with LC.

Worldwide, the incidence of kidney cancer has been increasing year by year, estimated to account for 4.0% of the total new cancer cases in 2021. 1 Approximately 90% of renal tumours are renal cell carcinoma (RCC), and approximately 80% of them are clear cell carcinoma. 2 An analysis of the SEER database indicates that RCC incidence has increased, on average, by 0.6% annually and death rates have decreased, on average, by 0.7% annually during 2006 and 2015 in the United States. 3 However, because of an insidious onset of symptoms in RCC, a remarkable proportion of patients are often diagnosed with locally advanced and distant tumours, and they have a poor five-year survival rate of about 10%. 4,5 Pinin (PNN) was initially identified and characterized as a desmosome-associated molecule as early as 1992. 6 The PNN gene

Background: The prognostic factors for patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy (WBRT)-based combined modality therapy were investigated. Materials and Methods: Out of 135 patients treated with WBRT, 47 (34.8%) received a radiation boost, 84 (62.2%) underwent systemic chemotherapy, and 39 (28.9%) were given epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Results: The mean survival time was 9.3 months, and the 1-year and 2-year survival rates were 46.3 and 16.1%, respectively. In univariate analysis, improved survival was associated with age < 60 years, no extracranial metastasis, Karnofsky performance score ≥ 70, ≥ 3 cycles of chemotherapy after diagnosis of brain metastases, combined treatment with EGFR-TKIs, and no metastases in the cerebellum. In multivariate analysis, the above prognostic factors maintained significance with the exception of age. In an additional analysis of the 58 patients with 1-3 brain metastases, combination of WBRT with radiation boost was associated with better survival. Conclusion: We confirm previously described prognostic factors. Moreover, we found the absence of cerebellar metastases to be an independent prognostic factor for favorable outcome.

No abstract

The clear cell renal cell carcinoma (ccRCC) is the main pathological subtype of renal cell carcinoma. Immune system evasion, one hallmark of cancer, contributes to cancer cells in escaping from the attack of immune cells. In order to identify potential prognostic biomarkers in ccRCC patients and immune cells fraction, we collected and downloaded profiles from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database. We obtained 2 modules significantly associated with tumor stage and immune cells; functional enrichment analysis showed that genes in the module ‘yellow’ were significantly enriched in proteins targeting to membrane and ribosome, as well as the oxidative phosphorylation pathway, while genes in the module ‘green’ mainly participate in molecular functions associated with immunity like activation of T cells. Four LncRNAs ( LINC00472, AL590094.1, AL365203.3 , and AC147651.3 ) and RPL27A and RPL22L1 in the module ‘yellow’ and two lncRNAs ( LINC00426 and AC129507.2 ) and five protein-coding genes ( CSF1, NOD2, ITGAE, CD7 , and PDCD1 ) in the module ‘green’ represented independent prognostic values in patients with ccRCC. Expression of LINC0042, NOD2, CD7 , and PDCD1 were significantly correlated with ratio of immune cells (like T cells CD8 and resting mast cells). LINC00426 , with significant correlation with immune cell fraction, shows potential prognostic value in ccRCC patients. Our findings provide a strategy in exploring biomarkers with prognostic significance and significant association with the fraction of immune cells.

ObjectiveThe aim of this study was to investigate the association between miR-1207-5p expression in peripheral blood and the chemosensitivity of primary gallbladder carcinoma (PGBC).MethodsA total of 85 patients with PGBC undergoing preoperative chemotherapy were divided into effective (n=18) and ineffective (n=67) groups. Another 70 healthy individuals were selected as the control group. An miR-1207-5p mimic (mimic group), an inhibitor (inhibitor group), and a negative control (NC group) sequence were transfected into human gallbladder carcinoma GBC-SD cells. Real-time quantitative polymerase chain reaction was used to determine miR-1207-5p expression. After 48 hours of cisplatin treatment, CCK-8 method was used to detect cell proliferation and flow cytometry were performed to examine cell apoptosis.ResultsmiR-1207-5p expression in peripheral blood was significantly associated with tumor node metastasis staging of PGBC (P<0.05). Before chemotherapy, miR-1207-5p expression in patients was higher than in healthy individuals (P<0.05). After chemotherapy, the effective group had lower miR-1207-5p expression than the ineffective group (P<0.05). The rates of positive expression of Ki67 protein in the effective group were significantly lower than those in the ineffective group (P<0.05). Receiver operating characteristic curves showed that the area under curve, sensitivity, and specificity of miR-1207-5p used to diagnose PGBC were 0.898, 77.6%, and 97.1% at a cutoff of 1.470, respectively. After 48 hours of cisplatin treatment, compared with the NC group and nontransfected (non-T) group, the mimic group had decreased rates of cell inhibition and apoptosis, but the inhibitor group had increased rates (all P<0.05). The expression levels of caspase3 protein were increased in the mimic group and decreased in the inhibitor group. Cell survival rates in the mimic group at different time points after cisplatin treatment were significantly higher than the corresponding rates in the NC and non-T groups, whereas the cell survival rates in the inhibitor group were significantly lower than the rates in the NC and non-T groups (all P<0.05). The concentration and action time of cisplatin were negatively associated with the cell survival rate in each group (all P<0.05).ConclusionCisplatin-based chemosensitivity of PGBC increased as expression of miR-1207-5p in peripheral blood declined. Thus, miR-1207-5p appears to be a promising and novel chemosensitizer for the treatment of PGBC.

No abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.